Sage Therapeutics Inc

Sage Therapeutics — Q1 2025 Earnings Presentation

9 slides from Sage Therapeutics's earnings presentation, Apr 29, 2025

  1. Slide 1: First Quarter 2025 Financial Results

    First Quarter 2025 Financial Results April 29, 2025

  2. Slide 2: Safe Harbor Statement

    • Safe Harbor Statement The slides presented today and the accompanying oral presentations contain forward-looking statements, − We may encounter unexpected safety or tolerability issues with respect to any of our product candidates or which may be identified by the use of words such as “may,” “migh

  3. Slide 3: Sage Therapeutics call participants

    Sage Therapeutics call participants Barry Greene Chris Benecchi Mike Quirk Chief Executive Officer Chief Operating Officer Chief Scientific Officer and Interim Head of R&D Sage Therapeutics © 2025 3

  4. Slide 4: 2025 core priorities

    2025 core priorities 1 2 3 Continued Targeted Financial Commercial Pipeline Focus Momentum Strategically invest in Develop novel programs in Optimize ZURZUVAE commercialization of diseases with high unmet need in commercialization in PPD, pipeline ZURZUVAE® in highly Neurodevelopmental Disorders & p

  5. Slide 5: Executing on goal to establish ZURZUVAE as the standard of care for women with PPD

    Executing on goal to establish ZURZUVAE as the standard of care for women with PPD >3,000 Shipments of ZURZUVAE to women with PPD in Q1 2025 ~80% >70% of prescriptions of women prescribed were written ZURZUVAE received by OBGYNs in it as their first new Q1 2025 treatment for PPD Please refer to the

  6. Slide 6: 2025 commercialization initiatives underway

    2025 commercialization initiatives underway SALESFORCE EXPANSION HCP & PATIENT WEBSITES Joint salesforce expansion to cover a 1 wider reach of HCPs who treat PPD 2 Build on ZURZUVAE branded media Expand social media influencer 3 campaigns/DTC Increase investment in disease state 4 awareness to suppo

  7. Slide 7: First Quarter 2025 Financial Results

    First Quarter 2025 Financial Results Item Q1 ‘25 Q1 ’24 Product revenue, net $0.0M $1.7M License and milestone revenue - related party $0.0M $0.0M Collaboration revenue - related party $13.8M $6.2M Other Collaboration revenue $0.2M $0.0M Total Revenue $14.1M $7.9M Cost of Revenues $0.7M $1.3M R&D Ex

  8. Slide 8: Our pipeline

    Our pipeline COMPOUND INDICATIONS PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 FDA APPROVED COLLABORATORS Neuropsychiatry ZURZUVAE®* Postpartum (zuranolone) Oral CIV Depression MARKETED Neurodevelopmental Disorders Behavioral symptoms SAGE-319 associated with PHASE 1 GABA Hypofunction neurodevelopmental dis

  9. Slide 9: Q&A

    Q&A Sage Therapeutics © 2025 9

Sage Therapeutics — Q1 2025 Earnings Presentation on 6ix